SEC Form 4 · accession 0001209191-15-043018
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kirk R Maples
Officer — SVP, Program Management
Period of report
May 12, 2015
Accepted (ET)
May 14, 2015 · 9:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 12, 2015 | M | 6,060 | $6.92 | A | 13,880 | D | |
| Common StockF1 | May 12, 2015 | S | 4,900 | $60.9695 | D | 8,980 | D | |
| Common StockF2 | May 12, 2015 | S | 1,160 | $61.4966 | D | 7,820 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $6.92 | May 12, 2015 | M | 6,060 | D | — | Mar 31, 2021 | Common Stock | 6,060 | 12,148 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.43 to $61.42, inclusive.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.44 to $61.52, inclusive.
- F3This option is fully vested and exercisable.